Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 3/2008

01-03-2008 | Original Article

Lung carcinomas do not induce T-cell apoptosis via the Fas/Fas ligand pathway but down-regulate CD3 epsilon expression

Authors: Heriberto Prado-Garcia, Dolores Aguilar-Cazares, Manuel Meneses-Flores, Jorge Morales-Fuentes, Jose Sullivan Lopez-Gonzalez

Published in: Cancer Immunology, Immunotherapy | Issue 3/2008

Login to get access

Abstract

Background

Non-small cell lung carcinoma (NSCLC) patients have impaired cellular immune responses. It has been hypothesized that tumor cells expressing Fas Ligand (FasL) induce in T lymphocytes: (a) apoptosis (tumor counterattack) and (b) down-regulation of CD3ζ expression. However, the hypothesis of tumor counterattack is still controversial.

Methods

We analyzed FasL expression on NSCLC cell lines and on tumor cells from lung adenocarcinoma patients by flow cytometry and immunocytochemistry. FasL mRNA expression was detected in NSCLC cell lines using RT-PCR, and functional FasL was evaluated on Fas-expressing Jurkat T-cells by annexin-V-FITC staining and by SubG1 peak detection. Also, the proapoptotic effect of microvesicles released from NSCLC cell lines in Jurkat T-cells was studied. Alterations in the expression levels of CD3ζ, CD3ε, and CD28 [measured as mean fluorescence intensity (MFI)] were determined in Jurkat T-cells after co-culture with NSCLC cell lines or tumor-derived microvesicles. Furthermore, the expression levels of CD3ζ and CD3ε in CD4+T and CD8+T lymphocytes from lung adenocarcinoma patients was studied.

Results

Our results indicate that NSCLC cells neither FasL expressed nor induced apoptosis in Jurkat T-cells. Tumor-derived microvesicles did not induce apoptosis in Jurkat T-cells. In contrast, NSCLC cell lines down-regulated CD3ε but not CD3ζ chain expression in Jurkat T-cells; this effect was induced by soluble factors but not by microvesicles. In lung adenocarcinoma patients, significant decreases of MFI values for CD3ε, but not CD3ζ, were found in CD4+T and CD8+T cells from pleural effusion compared to peripheral blood and in peripheral blood of patients compared to healthy donors.

Conclusions

Our data do not support the tumor counterattack hypothesis for NSCLC. Nonetheless, down-regulation of CD3ε in T-cells induced by NSCLC cells might lead to T-cell dysfunction.
Literature
1.
Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, Deho P, Squarcina P, Accornero P, Lozupone F, Lugini L, Stringaro A, Molinari A, Arancia G, Gentile M, Parmiani G, Fais S (2002) Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 195:1303–1316PubMedCrossRef
2.
Baniyash M (2004) TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol 4:675–687PubMedCrossRef
3.
Broderick L, Brooks SP, Takita H, Baer AN, Bernstein JM, Bankert RB (2006) IL-12 reverses anergy to T cell receptor triggering in human lung tumor-associated memory T cells. Clin Immunol 118:159–169PubMedCrossRef
4.
Chappell DB, Zaks TZ, Rosenberg SA, Restifo NP (1999) Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res 59:59–62PubMed
5.
Deakin AM, Singh K, Crowe JS, Ellis JH, Dalgleish A, Leicester RJ, Finlayson CJ, Miles WF, Life PF (1999) A lack of evidence for down-modulation of CD3 zeta expression in colorectal carcinoma and pregnancy using multiple detection methods. Clin Exp Immunol 118:197–204PubMedCrossRef
6.
Favre-Felix N, Fromentin A, Hammann A, Solary E, Martin F, Bonnotte B (2000) Cutting edge: the tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway. J Immunol 164:5023–5027PubMed
7.
Fischer K, Mackensen A (2003) The flow cytometric PKH-26 assay for the determination of T-cell mediated cytotoxic activity. Methods 31:135–142PubMedCrossRef
8.
Gastman BR, Atarshi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, Whiteside TL (1999) Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 59:5356–5364PubMed
9.
Gastman BR, Johnson DE, Whiteside TL, Rabinowich H (1999) Caspase-mediated degradation of T-cell receptor zeta-chain. Cancer Res 59:1422–1427PubMed
10.
Gastman BR, Johnson DE, Whiteside TL, Rabinowich H (2000) Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. Blood 95:2015–2023PubMed
11.
Huber V, Fais S, Iero M, Lugini L, Canese P, Squarcina P, Zaccheddu A, Colone M, Arancia G, Gentile M, Seregni E, Valenti R, Ballabio G, Belli F, Leo E, Parmiani G, Rivoltini L (2005) Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 128:1796–1804PubMedCrossRef
12.
Ibrahim R, Frederickson H, Parr A, Ward Y, Moncur J, Khleif SN (2006) Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism. Cancer 106:1065–1077PubMedCrossRef
13.
Kawasaki M, Kuwano K, Nakanishi Y, Hagimoto N, Takayama K, Pei XH, Maeyama T, Yoshimi M, Hara N (2000) Analysis of Fas and Fas ligand expression and function in lung cancer cell lines. Eur J Cancer 36:656–663PubMedCrossRef
14.
Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL (2005) Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res 11:1010–1020PubMed
15.
Kreyberg L, Liebow AA, Uehlinger EA (1981) Histological typing of lung tumours, 2nd edn. World Health Organization: International Histological Classification of Tumors, Geneva, pp 1–36
16.
Lopez-Gonzalez JS, Aguilar-Cazares D, Prado-Garcia H, Nieto-Rodriguez A, Mandoki JJ, Avila-Moreno F, Rivera RM, Chavarria-Garces J (2002) Lack of correlation between growth inhibition by TGF-beta and the percentage of cells expressing type II TGF-beta receptor in human non-small cell lung carcinoma cell lines. Lung Cancer 38:149–158PubMedCrossRef
17.
Lopez-Gonzalez JS, Prado-Garcia H, Aguilar-Cazares D, Molina-Guarneros JA, Morales-Fuentes J, Mandoki JJ (2004) Apoptosis and cell cycle disturbances induced by coumarin and 7-hydroxycoumarin on human lung carcinoma cell lines. Lung Cancer 43:275–283PubMedCrossRef
18.
Ma S, Ochi H, Cui L, He W (2003) FasL-induced downregulation of CD28 expression on jurkat cells in vitro is associated with activation of caspases. Cell Biol Int 27:959–964PubMedCrossRef
19.
Maher S, Toomey D, Condron C, Bouchier-Hayes D (2002) Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol 80:131–137PubMedCrossRef
20.
Maki A, Matsuda M, Asakawa M, Kono H, Fujii H, Matsumoto Y (2004) Decreased expression of CD28 coincides with the down-modulation of CD3zeta and augmentation of caspase-3 activity in T cells from hepatocellular carcinoma-bearing patients and hepatitis C virus-infected patients. J Gastroenterol Hepatol 19:1348–1356PubMedCrossRef
21.
Martinez-Lorenzo MJ, Anel A, Gamen S, Monleon I, Lasierra P, Larrad L, Pineiro A, Alava MA, Naval J (1999) Activated human T cell release bioactive Fas ligand and APO2 ligand in microvesicles. J Immunol 163:1274–1281PubMed
22.
Matsuda M, Petersson M, Lenkei R, Taupin JL, Magnusson I, Mellstedt H, Anderson P, Kiessling R (1995) Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 61:765–772PubMedCrossRef
23.
Meng Y, Kang S, Fishman DA (2005) Lysophosphatidic acid stimulates Fas ligand microvesicle release from ovarian cancer cells. Cancer Immunol Immunother 54:807–814PubMedCrossRef
24.
Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR, Kratzke RA (1997) Human lung carcinomas express Fas ligand. Cancer Res 57:1007–1012PubMed
25.
Onon TS, Kitchener HC, Duggan-Keen M, Stern PL (2003) No alteration in NK function or zeta chain expression in NK and T cells of cervical cancer patients. Gynecol Oncol 89:120–128PubMedCrossRef
26.
Prado-Garcia H, Aguilar-Cazares D, Flores-Vergara H, Mandoki JJ, Lopez-Gonzalez JS (2005) Effector, memory and naïve CD8+ T cells in peripheral blood and pleural effusion from lung adenocarcinoma patients. Lung Cancer 47:361–371PubMedCrossRef
27.
Radoja S, Saio M, Frey AB (2001) CD8+ tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ. J Immunol 166:6074–6083PubMed
28.
Restifo NP (2000) Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 6:493–495PubMedCrossRef
29.
Riccobon A, Gunelli R, Ridolfi R, De Paola F, Flamini E, Fiori M, Saltutti C, Petrini M, Fiammenghi L, Stefanelli M, Granato AM, Cuzzocrea DE, Amadori D (2007) Immunosuppression in renal cancer: differential expression of signal transduction molecules in tumor-infiltrating, near-tumor tissue, and peripheral blood lymphocytes. Cancer Invest 22:871–877CrossRef
30.
Schulze-Bergkamen H, Krammer PH (2004) Apoptosis in cancer—implications for therapy. Semin Oncol 31:90–119PubMedCrossRef
31.
Sikora J, Dworacki G, Giersz R, Zeromski J (2004) The role of monocytes/macrophages in TCR-zeta chain downregulation and apoptosis of T lymphocytes in malignant pleural effusions. J Biol Regul Homeost Agents 18:26–32PubMed
32.
Sikora J, Dworacki G, Zeromski J (1998) Expression of Fas and Fas ligand and apoptosis in tumor-associated lymphocytes and in tumor cells from malignant pleural effusions. Nat Immun 16:244–255PubMedCrossRef
33.
Sikora J, Zeromski J (2002) Expression of TCR-zeta chain and apoptosis in subpopulations of tumor-associated lymphocytes (TALs) from malignant pleural effusions. Folia Histochem Cytobiol 40:347–351PubMed
34.
Smith D, Sieg S, Kaplan D (1998) Technical note: aberrant detection of cell surface Fas ligand with anti-peptide antibodies. J Immunol 160:4159–4160PubMed
35.
Sobin L, Witzens M (1997) UICC TNM classification of malignant tumors. Wiley-Liss, New York
36.
Spiro SG, Silvestri GA (2005) One hundred years of lung cancer. Am J Respir Crit Care Med 172:523–529PubMedCrossRef
37.
Strater J, Walczak H, Hasel C, Melzner I, Leithauser F, Moller P (2001) CD95 ligand (CD95L) immunohistochemistry: a critical study on 12 antibodies. Cell Death Differ 8:273–278PubMedCrossRef
38.
Toomey D, Smyth G, Condron C, Kelly J, Byrne AM, Kay E, Conroy RM, Broe P, Bouchier-Hayes D (2003) Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: no association with prognosis identified in 3-year follow-up. Int J Cancer 103:408–412PubMedCrossRef
39.
Valenti R, Huber V, Iero M, Filipazzi P (2007) Tumor-released microvesicles as vehicles of immunosupression. Cancer Res 67:2912–2915PubMedCrossRef
40.
van de Corp, Falkenburg JH, Kester MG, Willemze R, Kluin-Nelemans JC (1999) Impaired expression of CD28 on T cells in hairy cell leukemia. Clin Immunol 93:256–262CrossRef
41.
Viard-Leveugle I, Veyrenc S, French LE, Brambilla C, Brambilla E (2003) Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma. J Pathol 201:268–277PubMedCrossRef
42.
Whiteside TL (1998) Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects. Adv Exp Med Biol 451:167–171PubMed
43.
Whiteside TL (2002) Tumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol 12:43–50PubMedCrossRef
44.
Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH (2001) Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61:4766–4772PubMed
Metadata
Title
Lung carcinomas do not induce T-cell apoptosis via the Fas/Fas ligand pathway but down-regulate CD3 epsilon expression
Authors
Heriberto Prado-Garcia
Dolores Aguilar-Cazares
Manuel Meneses-Flores
Jorge Morales-Fuentes
Jose Sullivan Lopez-Gonzalez
Publication date
01-03-2008
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 3/2008
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-007-0372-6

Other articles of this Issue 3/2008

Cancer Immunology, Immunotherapy 3/2008 Go to the issue

Original Article

The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays

Original Article

Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics

Original Article

Isolation of anti-MISIIR scFv molecules from a phage display library by cell sorter biopanning

Commentary

Toward the harmonization of immune monitoring in clinical trials: Quo vadis?

Original Article

Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity

Original Article

Plant-derived EpCAM antigen induces protective anti-cancer response

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits